13F-HR filed by GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2018-12-31, filed 2019-02-15, with 40 holding rows worth $791,189,000.
- Accession
- 0000930413-19-000592
- Filer
- CIK 1281446
- Filed
- 2019-02-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2018
A holdings report, 42 entries on the cover page, a total value of $791,189,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $791,189,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerJAY JEFFREY R028-12517
- included managerKROIN DAVID028-13262
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 7,622,256 | $61,512,000 | thousands by filing date | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 5,567,348 | $49,271,000 | thousands by filing date | |
| GLOBAL BLOOD THERAPEUTICS USD | 37890U108 | COM | 1,180,000 | $48,439,000 | thousands by filing date | |
| ACCELERON PHARMA INC | 00434H108 | COM | 1,036,575 | $45,143,000 | thousands by filing date | |
| ACADIA PHARMACEUTICALS INC | 004225108 | COM | 2,752,256 | $44,504,000 | thousands by filing date | |
| PTC THERAPEUTICS INC | 69366J200 | COM | 1,225,000 | $42,042,000 | thousands by filing date | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 2,769,527 | $38,884,000 | thousands by filing date | |
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 350,800 | $38,202,000 | thousands by filing date | |
| ZOGENIX INC. | 98978L204 | Common Stock | 1,000,000 | $36,460,000 | thousands by filing date | |
| AUDENTES THERAPEUTICS INC. | 05070R104 | Common Stock | 1,657,873 | $35,346,000 | thousands by filing date | |
| Vertex Pharmaceuticals Incorporated | 92532F100 | COM | 200,000 | $33,142,000 | thousands by filing date | put |
| PUMA BIOTECHNOLOGY INC | 74587V107 | COMMON STOCK | 1,379,700 | $28,077,000 | thousands by filing date | |
| ARRAY BIOPHARMA INC COM | 04269X105 | Stock | 1,850,000 | $26,363,000 | thousands by filing date | |
| SPARK THERAPEUTICS INC | 84652J103 | COM | 630,600 | $24,682,000 | thousands by filing date | |
| FIVE PRIME THERAPEUTICS INC. | 33830X104 | Common Stock | 2,398,409 | $22,305,000 | thousands by filing date | |
| INTERCEPT PHARMACEUTICALS IN | 45845P108 | COM | 200,000 | $20,158,000 | thousands by filing date | put |
| CYTOKINETICS INC | 23282W605 | COM NEW | 3,173,288 | $20,055,000 | thousands by filing date | |
| ZAFGEN INC | 98885E103 | COM | 3,598,392 | $17,812,000 | thousands by filing date | |
| FOAMIX PHARMACEUTICALS LTD | M46135105 | SHS | 4,047,561 | $14,531,000 | thousands by filing date | |
| SAVARA INC | 805111101 | COM | 1,819,195 | $13,771,000 | thousands by filing date | |
| TG THERAPEUTICS INC COM | 88322Q108 | Stock | 3,000,000 | $12,300,000 | thousands by filing date | |
| RVL PHARMACEUTICALS PLC | G6S41R101 | COM | 1,500,000 | $11,625,000 | thousands by filing date | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,418,489 | $11,164,000 | thousands by filing date | |
| MILLENDO THERAPEUTICS INC | 60040X103 | COM | 1,288,093 | $10,240,000 | thousands by filing date | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 492,100 | $10,226,000 | thousands by filing date | |
| ENANTA PHARMACEUTICALS INC | 29251M106 | COM | 143,481 | $10,163,000 | thousands by filing date | |
| AMAG PHARMACEUTICALS INC | 00163U106 | COM | 664,681 | $10,097,000 | thousands by filing date | |
| PROTEOSTASIS THERAPEUTICS IN | 74373B109 | COM | 3,045,423 | $9,867,000 | thousands by filing date | |
| MENLO THERAPEUTICS INC | 586858102 | COM | 2,204,407 | $9,082,000 | thousands by filing date | |
| NOVAVAX INC | 670002104 | COMMON STOCK | 4,500,000 | $8,280,000 | thousands by filing date | call |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 955,618 | $6,431,000 | thousands by filing date | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 400,000 | $4,556,000 | thousands by filing date | put |
| VOYAGER THERAPEUTICS INC | 92915B106 | COMMON STOCK | 365,132 | $3,432,000 | thousands by filing date | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 27,500 | $3,100,000 | thousands by filing date | |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 40,197 | $2,931,000 | thousands by filing date | |
| SAGE THERAPEUTICS INC | 78667J108 | COM | 26,000 | $2,491,000 | thousands by filing date | put |
| SAGE THERAPEUTICS INC | 78667J108 | COM | 26,000 | $2,491,000 | thousands by filing date | call |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 18,500 | $1,777,000 | thousands by filing date | |
| SUNESIS PHARMACEUTICALS INC | 867328700 | COM | 317,962 | $132,000 | thousands by filing date | |
| STREAMLINE HEALTH SOLUTIONS | 86323X106 | COM | 130,137 | $105,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000930413-19-000592 | this filing | 2019-02-15 | acceptance time not in the bulk data set |